Phoenix Biotech Acquisition (PBAXW) Peer Comparison

$0.03

$-0.05 (-64.29%)

As on 14-Feb-2024 17:56EDT

Market cap

$-- Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Market cap ($ Mln)	--	88
Revenue ($ Mln)	0	--
Net Profit ($ Mln)	-2.41	2.39
Net Margin (%)	-944.78	108.05
RoE (%)	--	10.81
Price to Earnings	--	262.50
Price-To-Book	--	5.04

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Operating Revenue	0.25	0.00
Cost of Revenue	0.00	2.19
Gross Profit	0.25	-1.57
Operating Expenses	3.85	0.87
Operating Profit (EBIT)	-1.33	-0.87
Other Income	0.00	2.21
Profit before Tax	-1.91	3.41
Provision for Tax	0.50	1.02
Profit after Tax (Net Income)	-2.41	2.39
Minority Interest	0.00	0.00
Consolidated Profit	0.00	2.41

Liabilities ($ Mln)

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Shareholder's Funds	-5.48	17.37
Minority Interest	0.00	0.00
Non-Current Liabilities	9.15	8.05
Current Liabilities	4.80	2.01
Total Liabilities	42.37	36.60

Assets ($ Mln)

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Non-Current Assets	0.00	27.21
Current Assets	8.47	0.23
Total Assets	42.37	36.60
Total Debt*	1.40	1.33
Net Current Assets	3.67	-1.79

Cashflow ($ Mln)

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Cash From Operating Activities	-1.09	-1.31
Cash Flow from Investing Activities	--	201.94
Cash from Financing Activities	-138.70	-200.75
Net Cash Inflow / Outflow	--	-0.13

Ratios

Profitability Ratios

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
ROCE (%)	-0.77	0.80
ROE (%)	-0.77	10.81
ROA (%)	-2.47	1.79
EBIT Margin (%)	-521.20	--
Net Margin (%)	-944.78	108.05
Cash Profit Margin (%)	--	--

Growth Ratios

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Revenue Growth (%)	--	--
EBIT Growth (%)	100.00	169.58
Net Profit Growth (%)	-100.00	514.17
EPS Growth (%)	--	460.22
Book Value Growth (%)	-111.67	-92.34

Valuation Ratios

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Price / Earnings	-1.48	58.99
Price / Book Value	0.40	2.24
Dividend Yield (%)	--	--
EV/EBITDA	-0.20	-15.58
Market Cap ($ Cr)	--	--

Solvency Ratios

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-0.25	0.08
Current Ratio	1.76	0.11
Quick Ratio	1.76	0.11
Interest Coverage	-8.06	2.79

Operating Efficiency Ratios

	Phoenix Biotech Acquisition (PBAXW)	Williams Rowland Acquisition (WRAC)
Debtors to sales (%)	0.00	--
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	--	127.50
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly